In a monumental leap forward for public health, Uganda has officially introduced a groundbreaking injectable HIV prevention medication, marking a transformative moment in the nation’s journey toward an AIDS-free future. The historic launch took place at the Former Akii-Bua Stadium in Lira City, signaling Uganda’s position as a global leader in adopting cutting-edge medical innovations to save lives and stop the spread of the virus.
This new tool, an injectable form of Pre-Exposure Prophylaxis known as Lenacapavir, is being hailed by health experts as a total game-changer. Unlike traditional prevention methods that require a daily pill, Lenacapavir is administered just twice a year. This long-acting formula is designed to overcome the common challenges of pill fatigue and the difficulty of maintaining a strict daily schedule, offering a discreet and highly effective shield against infection.
Leading the rollout, Dr. Jane Ruth Aceng, the Minister of Health, emphasized that while Uganda has made incredible strides, the battle is far from over. The statistics are a sobering reminder of why this innovation is so vital. While the country has successfully reduced annual new infections from 96,000 in 2010 to roughly 37,000 today, and over 1.4 million people are currently receiving life-saving treatment, a dangerous gap remains. Every single day, 100 people in Uganda still contract HIV. Most concerning is that 33 of these daily infections occur among the youth, particularly adolescent girls and young women. Furthermore, an estimated 150,000 Ugandans are living with the virus without even knowing their status.
Minister Aceng was clear in her message to the public: Lenacapavir is a powerful shield for prevention, but it is not a cure. She urged the population to remain vigilant, continue testing regularly, and adhere to proven prevention strategies. The introduction of this drug is meant to empower the community, not encourage a lapse in caution.
The scientific weight behind this rollout is substantial. Dr. Cissy Kityo Mutuluuza, the Executive Director of the Joint Clinical Research Centre, noted that the decision to implement this drug was based on rigorous African-led research. This evidence has already influenced global health standards and prompted the World Health Organization to update its guidelines. Efforts are already underway to ensure that more affordable, generic versions of the drug become available in the near future to ensure that every Ugandan who needs protection can access it.
Local health leaders in Lira, which remains a high-burden area for the virus, welcomed the intervention with both hope and a warning. Dr. Andrew Odur of the Lira Regional Referral Hospital pointed out that managing over 11,000 patients is a heavy task, and there is a growing, dangerous misconception that HIV is no longer a threat. Health officials are concerned that new medical breakthroughs might lead to a false sense of security, particularly among young people. They stressed that biomedical tools must be paired with education and behavioral changes to be truly effective.
Uganda’s proactive response has gained international applause and support. Mikael Cleverly, representing the United States Embassy, confirmed that Uganda was selected for this early rollout because of its robust health systems and proven track record in managing the HIV epidemic. Through partnerships with PEPFAR and the Global Fund, tens of thousands of Ugandans are expected to gain access to this life-saving injection by 2026 as part of a global mission to protect millions of people.
The launch of Lenacapavir is more than just a medical update; it is a call to action for every citizen. By combining modern science with community awareness and personal responsibility, Uganda is proving that the goal of ending AIDS as a public health threat by 2030 is not just a dream, but a rapidly approaching reality.